Mode
Text Size
Log in / Sign up
N/A N=500

Physiologic Assessment of Coronary Stenosis Following PCI

Coronary Artery Disease · Coronary Stenosis · Angina, Unstable · Angina, Stable

Enrolled (actual)
500
Serious AEs
2.6%
Results posted
May 2022
Primary outcome: Primary: Number of Participants With Residual Ischemia (iFR <0.90) — 112 participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
iFR pullback (Diagnostic_test)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Volcano Corporation
Primary completion
Jan 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Residual Ischemia (iFR <0.90)
112
SECONDARY
Cardiac Events
9; 3
SECONDARY
Target Vessel Failure
4; 2
SECONDARY
Quality of Life Change From Baseline to 12 Months Follow-up
21.42; 20.73
SECONDARY
Cardiac Mortality
0; 0
SECONDARY
Target Vessel MI
4; 2
SECONDARY
Target Vessel Revascularization
10; 3
SECONDARY
Recurrent Ischemia
6; 1
SECONDARY
Correlation Between iFR and Angiographic Visual Interpretation
0.03
SECONDARY
Number of Participants in Which the iFR Would Become Non-significant if a Focal Stenosis Demonstrated by iFR Pullback Were Treated With PCI
23
SECONDARY
Differentiation
93; 21
SECONDARY
Delta iFR
0.32; 5.65

Summary

This is a pilot study designed to assess the relationship between iFR (instantaneous wave-free ratio) pullback and the distribution of coronary atheroma/stenoses as assessed by Quantitative Coronary Angiography (QCA) post angiographically successful PCI (Percutaneous Coronary Intervention).

Eligibility Criteria

Inclusion Criteria

  • Subject must be > 18 years old
  • Subjects presenting with stable angina, silent ischemia or non-ST-elevation ACS (acute coronary syndrome) (unstable angina or biomarker positive)
  • Single vessel CAD with at least 2 separate lesions (≥10 mm apart) of ≥40% stenosis or a single long lesion of ≥20mm OR multi-vessel CAD, defined as at least 2 vessels with ≥40% stenosis
  • Pre-PCI iFR performed in all vessels intended for PCI
  • Pre-PCI iFR of 10 min) systolic blood pressure < 90 mmHg in absence of inotropic support or the presence of an intra-aortic balloon pump).
  • Ionotropic or temporary pacing requirement
  • Sustained ventricular arrhythmias
  • Prior CABG (Coronary Artery Bypass Graft)
  • Known ejection fraction ≤30%
  • Chronic Total Occlusion (CTO)
  • Known severe mitral or aortic stenosis.
  • Any known medical comorbidity resulting in life expectancy < 12 months.
  • Participation in any investigational study that has not yet reached its primary endpoint.
  • Known severe renal insufficiency (eGFR <30 ml/min/1.72 m2).
  • TIMI flow <3 at baseline
  • Intra-coronary thrombus on baseline angiography
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03084367). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search